China's New Exclusivity Rules Are Rewriting Orphan Drug StrategyLife SciencesMarket EntryChina BiopharmaOrphan DrugsClinical DevelopmentRare DiseaseNMPARegulatory ReformAug 5, 2026Global pharma has treated China as a secondary market for rare disease drugs for a simple reason: th...
